Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 8/20 | 0.61 |
| ▸ | HRH1 | P35367 | 1/20 | 0.54 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.53 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.53 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.53 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21852767 | 0.94 | ERAP2 (0.54) | RENERAP2ERAP1LNPEP | |
| SCHEMBL13563453 | 0.85 | REN (0.72) | RENERAP2ERAP1LNPEP | |
| SCHEMBL18862444 | 0.83 | REN (0.55) | RENHRH1ERAP2ERAP1LNPEP | |
| SCHEMBL18862365 | 0.83 | REN (0.67) | RENHRH1ERAP2ERAP1LNPEP | |
| SCHEMBL28381191 | 0.82 | REN (0.55) | REN | |
| SCHEMBL17325320 | 0.82 | SLC6A5 (0.55) | RENSLC15A2 | |
| SCHEMBL18857602 | 0.82 | REN (0.64) | RENHRH1ERAP2ERAP1LNPEP | |
| SCHEMBL14233122 | 0.81 | MMP2 (0.55) | RENHRH1ERAP2ERAP1LNPEP | |
| SCHEMBL22722179 | 0.81 | REN (0.65) | RENHRH1ERAP2ERAP1LNPEP | |
| SCHEMBL18862235 | 0.81 | REN (0.65) | RENHRH1ERAP2ERAP1LNPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180126013-A1 | RADIOTHERAPEUTIC AND COMPANION IMAGING AGENTS TO TARGET MC1R | WAKE FOREST UNIVERSITY | 2018-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180126013-A1 | RADIOTHERAPEUTIC AND COMPANION IMAGING AGENTS TO TARGET MC1R | MC1R, MC3R, MC5R | REN 3409/4885HRH1 686/4885ERAP2 2037/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.